Trupanion Inc header image

Trupanion Inc

TRUP

Equity

ISIN null / Valor 24738737

NASDAQ (2026-02-18)
USD 28.84-0.52%

Trupanion Inc
UMushroom community rating:

star star star star star
0.00 0 votes No rating yet
NegativeNeutralPositive

About company

Trupanion Inc, established in 2000, specializes in providing medical insurance plans for cats and dogs through a direct-to-consumer, subscription-based model. Operating in the United States, Canada, and Puerto Rico, the company offers comprehensive coverage that helps pet owners manage veterinary expenses by reimbursing eligible medical costs. Trupanion utilizes technology and data analytics to enhance the insurance process, aiming to deliver efficient and reliable services within the pet insurance market. By focusing on customer-centric solutions, Trupanion serves as a key player in ensuring pets receive necessary medical care without the financial burden on their owners.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results (16.01.2026):

Trupanion Inc — Third Quarter 2025: Trupanion reported strong Q3 2025 results with record quarterly profitability. Total revenue was $366.9M (up 12% YoY), driven by a 15% increase in subscription revenue to $252.7M. Net income was $5.9M ($0.14 basic / $0.13 diluted) versus $1.4M a year earlier, and adjusted EBITDA improved to $19.6M. Subscription enrolled pets grew 5% YoY to 1,082,412 (total enrolled pets were 1,654,414, down 2% YoY). Operating cash flow was $29.2M and free cash flow $23.9M. The company also completed a new three‑year $120M credit facility with PNC Bank to replace its prior facility and lower borrowing costs.

Revenue and top-line growth

Total Q3 2025 revenue was $366.9M, a 12% increase versus Q3 2024. Subscription revenue (the core business) was $252.7M, up 15% YoY. Year‑to‑date (first nine months) revenue was $1,062.5M, also up 12% versus the prior year.

Profitability and earnings

Q3 2025 net income was $5.9M ($0.14 basic / $0.13 diluted), versus $1.4M in Q3 2024. Nine‑month net income was $13.8M ($0.32 per share) compared with a net loss in the first nine months of 2024.

Adjusted EBITDA and non‑GAAP operating results

Adjusted EBITDA for Q3 2025 was $19.6M (versus $14.5M in Q3 2024). Total business adjusted operating income (non‑GAAP) was $40.85M for the quarter; subscription adjusted operating income (non‑GAAP) was $39.09M.

Cash flow and liquidity

Operating cash flow in Q3 was $29.2M and free cash flow was $23.9M (vs. $15.3M and $13.4M in Q3 2024). At September 30, 2025 Trupanion held $348.5M in cash and short‑term investments (including $58.5M outside the insurance entities) and had an additional $15.0M available under its prior credit facility before completing the new facility.

New credit facility

Trupanion entered a new three‑year $120M credit agreement with PNC Bank and used it to repay the prior facility. Management says the new facility carries a lower interest rate and enhances capital flexibility to support strategic investments.

Enrollment and unit economics

Subscription enrolled pets were 1,082,412 at quarter end, up 5% YoY; total pets enrolled were 1,654,414, down 2% YoY. Q3 monthly average revenue per pet was $82.01. Average pet acquisition cost (PAC) for the quarter was $290 and average monthly retention remained strong at 98.33%.

Cost structure and margins

Subscription cost of paying veterinary invoices was 70.1% of subscription revenue in Q3 (improving vs. 71.0% in Q3 2024). Subscription variable expenses were 8.9% and subscription fixed expenses were 5.6% of revenue, leaving subscription adjusted operating income at 15.5% of subscription revenue for the quarter (non‑GAAP).

Balance sheet and debt

Total assets were $880.2M and total liabilities $511.6M at September 30, 2025. Long‑term debt was $113.8M (current portion $0.75M). Management highlighted a strengthened capital structure and lower borrowing costs following the PNC facility.

Nine‑month performance

For the first nine months of 2025, Trupanion reported revenue of $1,062.5M (up 12%), subscription revenue of $727.9M (up 16%), adjusted EBITDA of $48.4M (vs. $26.7M prior year) and free cash flow of $50.0M (vs. $16.7M prior year).

Summarized from source with an LLMView Source

Key figures

-40.8%1Y
-50.3%3Y
-72.2%5Y

Performance

55.3%1Y
73.4%3Y
73.1%5Y

Volatility

Market cap

1253 M

Market cap (USD)

Daily traded volume (Shares)

853,248

Daily traded volume (Shares)

1 day high/low

49.64 / 47.85

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

0.00

0 votes
Performance:
starstarstarstarstar
0.00
Innovation:
starstarstarstarstar
0.00
Society:
starstarstarstarstar
0.00
Nature:
starstarstarstarstar
0.00

EQUITIES OF THE SAME SECTOR

Eurofins Scientific SE
Eurofins Scientific SE Eurofins Scientific SE Valor: 58317129
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.91%EUR 67.28
Teladoc Health Inc
Teladoc Health Inc Teladoc Health Inc Valor: 28438140
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.19%USD 4.66
Apellis Pharmaceuticals Inc
Apellis Pharmaceuticals Inc Apellis Pharmaceuticals Inc Valor: 30132056
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.92%USD 22.20
Dynavox Group AB
Dynavox Group AB Dynavox Group AB Valor: 114900704
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
3.29%SEK 83.25
PharmaSGP Holding SE
PharmaSGP Holding SE PharmaSGP Holding SE Valor: 55294050
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
3.13%EUR 33.00
Asker Healthcare Group AB
Asker Healthcare Group AB Asker Healthcare Group AB Valor: 143378021
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.39%SEK 63.69
Madrigal Pharmaceuticals Inc
Madrigal Pharmaceuticals Inc Madrigal Pharmaceuticals Inc Valor: 33395434
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.86%USD 491.49
Ste Virbac SA
Ste Virbac SA Ste Virbac SA Valor: 524407
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.41%EUR 367.00
Elevance Health Inc
Elevance Health Inc Elevance Health Inc Valor: 26124340
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.42%USD 346.24
Medtronic PLC
Medtronic PLC Medtronic PLC Valor: 25187155
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.16%USD 98.49